NASDAQ:TECH

Bio-Techne Stock Forecast, Price & News

$408.72
+3.58 (+0.88 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$402.68
Now: $408.72
$411.41
50-Day Range
$344.88
MA: $378.01
$405.14
52-Week Range
$189.33
Now: $408.72
$414.99
Volume182,600 shs
Average Volume200,127 shs
Market Capitalization$15.86 billion
P/E Ratio65.40
Dividend Yield0.32%
Beta1.13
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854
Employees2,300
Year Founded1981

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.69 million
Cash Flow$7.60 per share
Book Value$36.13 per share

Profitability

Net Income$229.30 million

Miscellaneous

Market Cap$15.86 billion
Next Earnings Date5/6/2021 (Confirmed)
OptionableOptionable

Headlines

Bio-Techne seals Asuragen acquisition
April 6, 2021 |  seekingalpha.com
Bio-Techne (NASDAQ:TECH) Shares Down 6.7%
March 29, 2021 |  americanbankingnews.com
Is Bio-Techne (TECH) A Smart Long-Term Buy?
March 11, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

62nd out of 2,010 stocks

Biological Products, Except Diagnostic Industry

8th out of 177 stocks

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$408.72
+3.58 (+0.88 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

Is Bio-Techne a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Bio-Techne stock.
View analyst ratings for Bio-Techne
or view top-rated stocks.

What stocks does MarketBeat like better than Bio-Techne?

Wall Street analysts have given Bio-Techne a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Techne wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Bio-Techne?

Bio-Techne saw a increase in short interest in March. As of March 15th, there was short interest totaling 406,400 shares, an increase of 45.9% from the February 28th total of 278,600 shares. Based on an average daily volume of 196,200 shares, the short-interest ratio is presently 2.1 days.
View Bio-Techne's Short Interest
.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Bio-Techne
.

How can I listen to Bio-Techne's earnings call?

Bio-Techne will be holding an earnings conference call on Thursday, May 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) announced its earnings results on Monday, February, 1st. The biotechnology company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.25. The biotechnology company had revenue of $224.30 million for the quarter, compared to the consensus estimate of $206.50 million. Bio-Techne had a net margin of 32.69% and a trailing twelve-month return on equity of 12.20%. The business's revenue for the quarter was up 21.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.08 EPS.
View Bio-Techne's earnings history
.

How has Bio-Techne's stock been impacted by COVID-19?

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TECH stock has increased by 126.3% and is now trading at $408.72.
View which stocks have been most impacted by COVID-19
.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Wednesday, February 3rd. Stockholders of record on Friday, February 12th will be paid a dividend of $0.32 per share on Friday, February 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.31%. The ex-dividend date of this dividend is Thursday, February 11th.
View Bio-Techne's dividend history
.

Is Bio-Techne a good dividend stock?

Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.32%. Bio-Techne does not yet have a strock track record of dividend growth. The dividend payout ratio of Bio-Techne is 33.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 21.88% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

What price target have analysts set for TECH?

10 equities research analysts have issued 1-year price objectives for Bio-Techne's shares. Their forecasts range from $220.00 to $440.00. On average, they anticipate Bio-Techne's stock price to reach $367.50 in the next twelve months. This suggests that the stock has a possible downside of 10.1%.
View analysts' price targets for Bio-Techne
or view top-rated stocks among Wall Street analysts.

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the following people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 61, Pay $2.86M) (LinkedIn Profile)
  • Mr. James T. Hippel, Exec. VP of Fin. & CFO (Age 50, Pay $1.15M) (LinkedIn Profile)
  • Ms. Brenda S. Furlow, Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer (Age 63, Pay $821.24k) (LinkedIn Profile)
  • Mr. Norman David Eansor, Pres of Protein Sciences Segment (Age 60, Pay $1.08M) (LinkedIn Profile)
  • Mr. Kim Kelderman, Pres of Diagnostics & Genomics (Age 54, Pay $972.4k) (LinkedIn Profile)
  • David Clair, Sr. Director of Investor Relations & Corp. Devel. (LinkedIn Profile)
  • Mr. Gerry Andros, VP of Sales and Marketing
  • Mr. Struan Robertson, VP of HR (LinkedIn Profile)
  • Mr. Robert M. Gavin, Sr. VP of Analytical Solutions Division (Age 53) (LinkedIn Profile)
  • Mr. Kevin S. Gould, Sr. VP of Diagnostics Reagents Division (Age 55) (LinkedIn Profile)

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne CEO Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among Bio-Techne's employees.

Who are some of Bio-Techne's key competitors?

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and The Boeing (BA).

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%), Fulcrum Equity Management (0.01%) and Pacer Advisors Inc. (0.01%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne
.

Which major investors are buying Bio-Techne stock?

TECH stock was acquired by a variety of institutional investors in the last quarter, including Fulcrum Equity Management, Pacer Advisors Inc., and State of Alaska Department of Revenue. Company insiders that have bought Bio-Techne stock in the last two years include Charles R Kummeth, and Robert V Baumgartner.
View insider buying and selling activity for Bio-Techne
or or view top insider-buying stocks.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $408.72.

How much money does Bio-Techne make?

Bio-Techne has a market capitalization of $15.86 billion and generates $738.69 million in revenue each year. The biotechnology company earns $229.30 million in net income (profit) each year or $3.86 on an earnings per share basis.

How many employees does Bio-Techne have?

Bio-Techne employs 2,300 workers across the globe.

Does Bio-Techne have any subsidiaries?

The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., CLINIQA Corporation, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.

When was Bio-Techne founded?

Bio-Techne was founded in 1981.

What is Bio-Techne's official website?

The official website for Bio-Techne is www.bio-techne.com.

Where are Bio-Techne's headquarters?

Bio-Techne is headquartered at 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]


This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.